The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Cited by
The SYK tyrosine kinase: A crucial player in diverse biological functions
Mócsai, A., Ruland, J., & Tybulewicz, V. L. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2765 · Cited by 1,368
“An R112-related inhibitor, R406 (Rigel), as well as its orally bioavailable prodrug, fostamatinib (R788; Rigel/Astra Zeneca), delayed the onset and reduced the severity of autoimmune arthritis in animal model”
BackgroundSyk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence
Gross, O., Poeck, H., Bscheider, M., Dostert, C., Hannesschläger, N., Endres, S., Hartmann, G., Tardivel, A., Schweighoffer, E., Tybulewicz, V., et al. (2009) · Nature · doi:10.1038/nature07965 · Cited by 819
Fluorine‐Containing Drugs Approved by the FDA in 2018
Mei, H., Han, J., Fustero, S., Medio‐Simon, M., Sedgwick, D. M., Santi, C., Ruzziconi, R., & Soloshonok, V. A. (2019) · Chemistry – A European Journal · doi:10.1002/chem.201901840 · Cited by 454
Kinase inhibition in autoimmunity and inflammation
Zarrin, A. A., Bao, K., Lupardus, P., & Vucic, D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0082-8 · Cited by 431
An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis
Weinblatt, M. E., Kavanaugh, A., Genovese, M. C., Musser, T. K., Grossbard, E. B., & Magilavy, D. B. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000500 · Cited by 381
Self-citationWeinblatt, M. E., Kavanaugh, A., Burgos‐Vargas, R., Dikranian, A. H., Medrano‐Ramirez, G., Morales‐Torres, J. L., Murphy, F. T., Musser, T. K., Straniero, N., Vicente‐Gonzales, A. V., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23992 · Cited by 342
Self-citationTargeting innate immunity protein kinase signalling in inflammation
Gaestel, M., Kotlyarov, A., & Kracht, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2829 · Cited by 316
Podolanczuk, A., Lazarus, A. H., Crow, A. R., Grossbard, E., & Bussel, J. B. (2009) · Blood · doi:10.1182/blood-2008-07-166439 · Cited by 263
Self-citationRecent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies
Mueller, A.-L., Payandeh, Z., Mohammadkhani, N., Mubarak, S. M. H., Zakeri, A., Alagheband Bahrami, A., Brockmueller, A., & Shakibaei, M. (2021) · Cells · doi:10.3390/cells10113017 · Cited by 256
Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases
Patterson, H., Nibbs, R., McInnes, I., & Siebert, S. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12248 · Cited by 199
Back to the future: oral targeted therapy for RA and other autoimmune diseases
O'Shea, J. J., Laurence, A., & McInnes, I. B. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.7 · Cited by 115
Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development
Sardar, S., & Andersson, Å. (2016) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2015.1125917 · Cited by 50
Metadata
- Authors
- Pine, P. R., Chang, B., Schoettler, N., Banquerigo, M. L., Wang, S., Lau, A., Zhao, F., Grossbard, E. B., Payan, D. G., & Brahn, E.
- Venue
- Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 124
- Issue
- 3
- Pages
- 244-257
- ISSN
- 1521-6616 (ISSN-L)
- OpenAlex
- W1983513155
- Cited by
- 208
- References
- 1
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.